GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Shiller PE Ratio

Ardelyx (Ardelyx) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ardelyx Shiller PE Ratio Historical Data

The historical data trend for Ardelyx's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Shiller PE Ratio Chart

Ardelyx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ardelyx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ardelyx's Shiller PE Ratio

For the Biotechnology subindustry, Ardelyx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ardelyx's Shiller PE Ratio falls into.



Ardelyx Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ardelyx's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Ardelyx's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.13/129.4194*129.4194
=-0.130

Current CPI (Dec. 2023) = 129.4194.

Ardelyx Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.172 99.695 -0.223
201406 0.180 100.560 0.232
201409 0.004 100.428 0.005
201412 -0.210 99.070 -0.274
201503 -0.190 99.621 -0.247
201506 0.420 100.684 0.540
201509 -0.700 100.392 -0.902
201512 -0.650 99.792 -0.843
201603 -0.700 100.470 -0.902
201606 -0.830 101.688 -1.056
201609 -0.650 101.861 -0.826
201612 -0.650 101.863 -0.826
201703 -0.590 102.862 -0.742
201706 -0.540 103.349 -0.676
201709 -0.440 104.136 -0.547
201712 0.210 104.011 0.261
201803 -0.360 105.290 -0.443
201806 -0.420 106.317 -0.511
201809 -0.390 106.507 -0.474
201812 -0.450 105.998 -0.549
201903 -0.420 107.251 -0.507
201906 -0.410 108.070 -0.491
201909 -0.370 108.329 -0.442
201912 -0.270 108.420 -0.322
202003 -0.250 108.902 -0.297
202006 -0.280 108.767 -0.333
202009 -0.200 109.815 -0.236
202012 -0.320 109.897 -0.377
202103 -0.340 111.754 -0.394
202106 -0.450 114.631 -0.508
202109 -0.420 115.734 -0.470
202112 -0.310 117.630 -0.341
202203 -0.210 121.301 -0.224
202206 -0.190 125.017 -0.197
202209 -0.140 125.227 -0.145
202212 0.060 125.222 0.062
202303 -0.130 127.348 -0.132
202306 -0.080 128.729 -0.080
202309 0.030 129.860 0.030
202312 -0.130 129.419 -0.130

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ardelyx  (NAS:ARDX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ardelyx Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ardelyx's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ardelyx (Ardelyx) Business Description

Traded in Other Exchanges
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Executives
David P. Rosenbaum officer: Chief Development Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Justin A Renz officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer officer: See Remarks 78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks officer: See Remarks C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
Laura A Williams officer: Chief Medical Officer 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Robert Ora Felsch officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Michael Raab director, officer: President & CEO 1119 ST PAUL STREET, BALTIMORE MD 21202
Susan Rodriguez officer: Chief Commercial Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Jeffrey W Jacobs officer: VP, Chemistry C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli officer: See Remarks C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010